News | April 25, 2025
We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer
Bayer expects 2025 to be the most difficult year of its turnaround
Bayer expects 2025 to be the most difficult year of its turnaround
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
EBITDA before special items falls 1.3 percent to € 4.41 billion
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Juergen Eckhardt joined Bayer in 2016 to help start Leaps by Bayer
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Subscribe To Our Newsletter & Stay Updated
